StockUS listing USCRISNASDAQHealthcareEarnings Deterioration

Curis Inc(CRIS) Stock Analysis | Healthcare

USD --+0.00%
Reward44Moderate
Risk78High
75%Data
Revenue down 66% YoY
USD —+0.00 (+0.00%) Previous close · NASDAQ
Market cap 4.06M
Reward Ratingⓘ44 Moderate reward assessment · 75% data coverage
Bottom 25% of stocksView factors
Risk Ratingⓘ78 High risk assessment
Risk factors availableUnlock details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on CRIS to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Curis Inc?

, a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States.

AI Brief Pro

The brief on Curis Inc

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is Curis Inc?

, a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small-molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single-arm expansion trial in patients with relapsed/refractory primary central nervous system lymphoma. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 4.06M.

Financial Highlights

Investment Breakdown

Growth
Growth trend is developing — watch for revenue consistency over upcoming quarters.
Profitability
Thin or inconsistent margins weigh on earnings quality.
Risk
Elevated volatility implies higher downside and expectation risk.
Valuation
Valuation appears fair relative to current fundamentals.

OpenBook Logo Analysis

Reward: Moderate (44)
Company Information
SectorHealthcare
IndustryBiotechnology
P/E Ratio0.0277
Beta3.246
Insider Activity
12M windowQuiet
Fewer than three real open-market insider trades in the last 12 months. Mechanical activity (option exercises, RSU vests) is excluded from the signal.